Logo     Print Page  Close Window

SEC Filings

FIBROCELL SCIENCE, INC. filed this Form S-3 on 01/18/2019
Entire Document

This prospectus contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this prospectus or the documents incorporated herein by reference regarding our strategy, future operations, future product research or development, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “goals,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
The forward-looking statements in this prospectus include, among other things, statements about:
our review of strategic alternatives, including the possible sale or merger of our company;

our expectation that our existing cash resources will be sufficient to enable us to fund our operations into the fourth quarter of 2019;

future expenses and capital expenditures;

our estimates regarding expenses, future revenues, capital requirements and needs for, and ability to obtain, additional financing;

our plans to address our future capital requirements and the consequences of failing to do so;

our need to raise substantial additional capital to fund our operations;

our plans to report interim data from patients from the Phase 2 portion of our Phase 1/2 clinical trial for FCX-007 and provide a trial update in the first quarter of 2019;

our plans to use data from the Phase 1/2 clinical trial of FCX-007 to support a petition for Regenerative Medicine Advanced Therapy or Breakthrough Therapy Designation for FCX-007;

our plans to submit a Phase 3 clinical trial protocol for FCX-007 to the FDA in the first quarter of 2019 while continuing to collect additional data from the Phase 2 portion of the Phase 1/2 clinical trial of FCX-007;

our plans to initiate a Phase 3 clinical trial for FCX-007 in the first half of 2019;

our product development goals under our collaborations with Precigen, Inc., a wholly owned subsidiary of Intrexon Corporation, for our product candidates;

the potential benefits of Fast Track, Orphan Drug and Rare Pediatric Disease designations;

the potential advantages of our product candidates and technologies; and

the effect of legal and regulatory developments.
We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and our stockholders should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this prospectus, particularly in the “Risk Factors” section, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.